Published 2017

Read in Norwegian

Publication details

Journal : eLIFE , vol. 6 , 2017

International Standard Numbers :
Printed : 2050-084X
Electronic : 2050-084X

Publication type : Academic article

Contributors : Pateraki, Irini; Andersen-Ranberg, Johan; Jensen, Niels Bjerg; Wubshet, Sileshi Gizachew; Heskes, Allison Maree; Forman, Victor; Hallström, Björn M.; Hamberger, Britta; Motawia, Mohammed Saddik; Olsen, Carl Erik; Staerk, Dan; Hansen, Jørgen; Møller, Birger Lindberg; Hamberger, Björn

If you have questions about the publication, you may contact Nofima’s Chief Librarian.

Kjetil Aune
Chief Librarian


Forskolin is a unique structurally complex labdane-type diterpenoid used in the treatment of glaucoma and heart failure based on its activity as a cyclic AMP booster. Commercial production of forskolin relies exclusively on extraction from its only known natural source, the plant Coleus forskohlii, in which forskolin accumulates in the root cork. Here, we report the discovery of five cytochrome P450s and two acetyltransferases which catalyze a cascade of reactions converting the forskolin precursor 13R-manoyl oxide into forskolin and a diverse array of additional labdane- type diterpenoids. A minimal set of three P450s in combination with a single acetyl transferase was identified that catalyzes the conversion of 13R-manoyl oxide into forskolin as demonstrated by transient expression in Nicotiana benthamiana. The entire pathway for forskolin production from glucose encompassing expression of nine genes was stably integrated into Saccharomyces cerevisiae and afforded forskolin titers of 40 mg/L.